Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04046549 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT04046549 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 25 participants.
The verdict
NCT04046549, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of dual costimulation blockade with VIB4920 in combination of belatacept in adult male or female recipients of a renal allograft from a deceased, living unrelated or human leukocyte antigen (HLA) non-identical living related donor.
Interventions
- DRUG Thymoglobulin
- DRUG Methylprednisolone
- DRUG VIB4920
- DRUG Belatacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2019-10-30 |
| Est. Completion | 2023-03-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04046549
The ClinicalTrials.gov registry entry for NCT04046549 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Thymoglobulin is the first listed.
NCT04046549 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04046549 about?
NCT04046549 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant". The purpose of this study is to evaluate the efficacy, safety and tolerability of dual costimulation blockade with VIB4920 in combination of belatacept in adult male or female recipients of a renal allograft from a deceased, living unrelated or human leukocyte antigen (HLA) non-identical living rela...
What is the current status of trial NCT04046549?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2019-10-30. Estimated completion is 2023-03-22.
What interventions are being tested in trial NCT04046549?
The interventions under investigation include: Thymoglobulin (DRUG), Methylprednisolone (DRUG), VIB4920 (DRUG), Belatacept (DRUG).
Who is sponsoring clinical trial NCT04046549?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.